Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Neonatal Care Unit receives donation to expand capacity
2015-10-28

  

With the best care and technology available,
the survival rate of premature
babies is about 85%. The neonatal intensive
care unit at the Universitas hospital can now
expand its capacity thanks to a donation of
R1 million by the Discovery fund.
From the left is Prof André Venter.
Head: Department of Paediatrics and
Child Health at the UFS, and mrs Ruth Lewin,
Head: Corporate Sustainability at Discovery. 

The smallest people need the greatest care. This care is being provided by the neonatal unit in the Children’s Wing of the Universitas Hospital. This project of the University of the Free State (UFS), under the leadership of Prof Andre Venter, has led to several miracles regarding child health since its inception.

Now, thanks to a donation of R1 million rand from the Discovery fund, this unit can expand its capacity and treat more premature babies.

About 14% of babies in South Africa are born before the 37th week of pregnancy. These babies are born with a very low birth weight, and are in need of critical care. The neonatal intensive-care unit at Universitas Hospital is currently equipped to take care of about 14 premature babies at a time, from birth to discharge. However, because of the high incidence of premature births in the hospital’s service area, the unit needs about 45 beds.

The aim of the Children’s Wing Project is to expand the neonatal intensive-care unit in order to meet the demands of the hospital’s service area, which reaches as far as the Southern Cape. The Discovery Fund recently donated R1 million to the project, which will be used to expand the capacity of the neonatal intensive-care unit.

“With the best care and technology available, the survival rate of premature babies is about 85%. Without this, half of all premature babies would die,” says Prof Venter, Head: Department of Paediatrics and Child Health at the UFS.

“This is the reason why private and public partnerships, such as the one with Discovery, are essential to make specialised services available to the most vulnerable people. Discovery has made a significant contribution to the project without which we would not have been able to expand the capacity of the unit



We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept